Search - tctmd.com

Displaying 1 - 20 of 41

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Yael L. Maxwell

April 03, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

News Daily News

Nonfatal MI Not a Death Surrogate in Cardiology: Meta-analysis

Caitlin E. Cox

October 27, 2021

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

News Conference News AHA 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Yael L. Maxwell

November 16, 2018

Advertisement

Year in Review: Top Prevention Stories of 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Nonfatal MI Not a Death Surrogate in Cardiology: Meta-analysis

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Top News in Clinical Cardiology: 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content